A bloodspot assay for testosterone has been developed using an antiserum raised against testosterone-3-carboxymethyloxime-bovine serum albumin (T-3 CMO-BSA) conjugate and 125I-T-3CMO-histamine tracer. The method has a detection limit of 0-4nmol/L with between-batch precision of less than 15% for testosterone values between 0·9 and 2·0 nmol/L and less than 10% for values greater than 2·0 nmol/l., Recovery of 4 nmol/L testosterone spiked into whole blood samples from 16 women (with un spiked bloodspot testosterone concentrations ranging from 0-4 to 3·7nmol/L) was 100·9%. Bloodspot testosterone concentration was measured in thirty 6-9 day old infants (19 boys, 11 girls) with an absolute range in boys of < 0·4-2·3 nmol/L and in girls of < 0-4 nmol/L, In preterm infants (12 boys, 12 girls) of varying birth gestation and postnatal age, levels were higher than in term infants, with boys showing a rise with increasing postnatal age. Daytime bloodspot profiles in four children on replacement therapy for congenital adrenal hyperplasia demonstrated consistently low testosterone levels in the presence of moderately elevated early morning l7-hydroxyprogesterone concentrations, thus indicating adequate treatment. The bloodspot testosterone assay can be applied to the study of androgen physiology in preterm neonates as well as for monitoring treatment in disorders such as congenital adrenal hyperplasia.
SUMMARY. A bloodspot assay for testosterone has been developed using an antiserum raised against testosterone-3-carboxymethyloxime-bovine serum albumin (T-3 CMO-BSA) conjugate and 125I-T-3CMO-histamine tracer. The method has a detection limit of 0-4nmol/L with between-batch precision of less than 15% for testosterone values between 0·9 and 2·0 nmol/L and less than 10% for values greater than 2·0 nmol/l., Recovery of 4 nmol/L testosterone spiked into whole blood samples from 16 women (with un spiked bloodspot testosterone concentrations ranging from 0-4 to 3·7nmol/L) was 100·9%. Bloodspot testosterone concentration was measured in thirty 6-9 day old infants (19 boys, 11 girls) with an absolute range in boys of < 0·4-2·3 nmol/L and in girls of < 0-4 nmol/L, In preterm infants (12 boys, 12 girls) of varying birth gestation and postnatal age, levels were higher than in term infants, with boys showing a rise with increasing postnatal age. Daytime bloodspot profiles in four children on replacement therapy for congenital adrenal hyperplasia demonstrated consistently low testosterone levels in the presence of moderately elevated early morning l7-hydroxyprogesterone concentrations, thus indicating adequate treatment. The bloodspot testosterone assay can be applied to the study of androgen physiology in preterm neonates as well as for monitoring treatment in disorders such as congenital adrenal hyperplasia.
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Patterns of testosterone production during the neonatal and infancy periods in healthy term infants show an intriguing sex difference. At birth testosterone is not only higher in boys than in girls but also appears to rise significantly at about 3 h of age, associated with a transient rise in luteinizing hormone. 1 Concentrations fall rapidly during the first 5 days of life 2,] but there are then few data until day 19, following which there is a gradual rise in male testosterone levels to a peak at 4-8 weeks of age, associated with a further surge in gonadotrophin secretion." Thereafter, testosterone declines to prepubertal concentrations by 6 months of age."
Information about these patterns of testosterone secretion in early life is largely derived Correspondence: Dr P J Wood. E-mail: pjwendo@btinternet.com from cross-sectional data since longitudinal studies are hampered by the relatively large volumes of whole blood required for conventional plasma testosterone assays. In the study by Corbier et al,' of testosterone during the first 24 h of life, repeated venepuncture of 1mL of blood was undertaken and the number of infants was small.
Measurement of steroids in saliva-" is an alternative, non-invasive and non-stressful method of investigation but collection is unreliable in infants and young children. A further alternative is the use of filter paper bloodspot assays with their major advantage of using microlitre volumes of blood, which are easy to obtain. Although relatively invasive, they do permit testing oflarger numbers and such assays are well established for many steroids including l7-hydroxyprogesterone,7 androstenedione/ and cortisol.f-'" A bloodspot testosterone assay would facilitate further study of the pattern and significance of the testosterone surge in infancy. A second application would be monitoring treatment of congenital adrenal hyperplasia (CAH) in girls and prepubertal boys. Over 90% of cases of CAH are due to deficiency of adrenal 2 I-hydroxylase. Cortisol and often aldosterone production is inadequate and the excessive production of precursor steroids and adrenal androgens, if untreated, leads to precocious puberty and stunting of growth. Doses of glucocorticoid replacement aim to suppress the excess androgen secretion and yet permit normal growth and reproduction. Profiles of bloodspot 17-hydroxyprogesterone (l7-0HP), one of the precursor steroids, have been advocated to monitor control but this is only an indirect measure of adrenal androgen production and has the added disadvantage of short-term fluctuations with individual steroid replacement doses.'! Serum androstenedione or testosterone measurements give a more direct indication of androgen production for monitoring replacement therapy.'? This paper describes the development of a bloodspot testosterone assay using a simple adaptation of an existing plasma assay. The method has been applied to the study of term infants at 6-9 days of age and of a number of preterm infants and children with CAH.
METHODS
All reagents were 'Analar' grade from BDH Ltd (Poole, UK) unless stated otherwise.
Testosterone tracer Testosterone-3-CMO-histamine-[1 25I
] was prepared in-house following the method of Hunter et al. 13 Preparation of testosterone-free blood and bloodspot testosterone standards Testosterone-free blood, used to make bloodspot standards for the assay, was prepared by charcoal-treating plasma separated from 100mL heparinized whole blood. An equal volume of isotonic saline was added to the centrifuged red cells and after gently mixing these were left overnight at 4°C. Red cells were then centrifuged and the saline wash discarded. The plasma was stirred with charcoal (Norit GSX, 20g/100 mL) for 24 h at 4°C. Charcoal was sedimented by centrifugation at 3000 rpm for IS min and the supernatant was then filtered [Seitz Tufenfilter Ann Clin Biochem 1999: 36 07853 Size 60; Seitz Filtration (GB) Ltd, Ledbury, Herts, UK] to remove charcoal fines. A serum testosterone assay was performed on the stripped plasma to confirm that testosterone was undetectable.
Stripped plasma and washed red cells were then re-mixed in proportions 55:45. Testosterone standards were prepared in this matrix at final concentrations of O· 31 to 40 nmol/L and a range of bloodspot standards prepared on filter paper (Grade 2992, Anderman & Co Ltd, Kingstonupon-Thames, Surrey, UK). Zero standards were also prepared from the testosterone-free blood. These were left to dry overnight at room temperature and then stored in an airtight container at room temperature. Cards from the same batch of filter paper were used for all patient and control samples analysed as part of this study.
Bloodspot testosterone assay method Duplicate 6 mm diameter bloodspots were punched into wide-necked screw-topped glass tubes (Epsom Glass Industries Ltd, Epsom, Surrey, UK) from standard, control or test filter paper cards. Each was eluted with 500 ul, assay buffer (0·05 nmol/L phosphate, pH 7·4, containing sodium chloride IS g/L, sodium azide I g/L and BSA 2 giL) in a shaking water bath at 37"C for 30 min.
Ether (3·0 mL) was then added to each tube and after vortexing for 4 periods of 1 min, tubes were centrifuged at 3000 rpm for 10 min and the lower aqueous layer frozen in a solid CO 2 / methylated spirit freezing bath. Solvent layers were then decanted into lOx 76 mm glass tubes and the solvent evaporated under a stream of dry nitrogen at 37"C.
Testosterone concentrations were determined in the dried extracts by the addition of 200 ilL of assay buffer containing 20000cpm (I0nCi) of testosterone-3-CMO-histamine-[1 2sI] tracer and 200 ilL of assay buffer containing sheep anti-testosterone-3-CMO-BSA antiserum (Guildhay Ltd, Guildford, UK) at a working dilution of I in 125000. Tubes were incubated at room temperature for 2 h. Bound radioactivity was separated by the addition of 100ilL of a suspension of anti-sheep Sac-Cel (IDS Ltd, Tyne and Wear, UK). After mixing, tubes were incubated for a further 30 min at room temperature, and 1·0 mL water was added before centrifugation, aspiration of supernatants and counting of pellets.
Assay validation
Recovery of a spike of 4 nrnol/L testosterone added to heparinized whole blood samples from 16 women prior to preparation of bloodspots was 100·9%±4·3% (mean±SEM). Inter-assay imprecision was less than 10% for bloodspot testosterone concentrations over 2 nrnol/L and less than 15% for concentrations over 0·9 nrnol/L, Figure I illustrates a typical standard curve and a precision profile using data from six consecutive batches, calculated according to the method described by Wood et al. 14 The detection limits for the assay (defined as the testosterone concentration equivalent to mean zero standard count -2SD imprecision at zero) was 0-4 nmol/L, Assessment of the cross-reactivity of seven related steroids in the assay showed that the only steroids with significant cross-reactivity were 50(dihydrotestosterone (22%) and 5-androstene 3fJ, 17fJ diol (19%).
Bloodspot testosterone results were compared with the corresponding plasma testosterone result on 40 samples using our routine laboratory plasma assay (see below). The 
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Bloodspot 170( hydroxyprogesterone assay Bloodspot 170( hydroxyprogesterone was measured by the routine laboratory method." Between-batch imprecision (%CV) for the assay controls ranged from 14·6% at 12·6 nmol/L to 8·9% at 370 nmol/L, Extraction plasma testosterone assay Plasma testosterone concentrations were analysed by the assay used for a routine clinical biochemistry service. Samples were extracted with ether and the dried extracts assayed by radioimmunoassay using Guildhay antisera Code S040 and T-3-CMO-histamine-[ 125 1) tracer. Between-batch imprecision for control samples ranged from 11·7% at a concentration of 2·6 nmol/L to 7-4% at a value of 17·9 nmol/L, SUBJECTS All bloodspots were collected onto the same batch of Anderman 2992 filter paper as was used for bloodspot standards. Bloodspots were accepted if the paper was saturated from front to back over a circular area of diameter greater than 6 mm. Blood samples taken from young infants were for routine diagnostic purposes only.
Term infants
Duplicate bloodspots were obtained from 30 neonates (19 boys, II girls) 6-9 days after delivery, as part of the routine screening for phenylketonuria and hypothyroidism. 
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Preterm infants
Bloodspots were collected from 24 infants (12 boys, 12 girls) at the same time as their routine weekly blood profiles. Their gestation at birth ranged from 25 to 34 weeks and postnatal age at the time of collection ranged from 7 to 71 days. Five infants (two boys, three girls) had serial samples collected.
Congenital adrenal hyperplasia
Four patients (two boys, two girls, age range 1'8-5-4 years) with CAH due to 21-hydroxylase deficiency were studied at the same time as a routine profile for 17-0HP was done. Bloodspots (four for each collection time) were collected onto filter paper at 0800, 1200, 1800 and 2300 h and stored at room temperature prior to analysis. Serial samples were obtained over the first 12 months of life from one infant born with ambiguous genitalia, subsequently confirmed to be a female with CAH due to 21-hydroxylase deficiency.
RESULTS
Bloodspot testosterone concentrations in normal infants at 6-9 days of age are illustrated in Fig. 3 . All girls had concentrations below the detection limit for the method (0-4 nmoljL) as did many of the boys. Higher concentrations were seen in some boys. Absolute ranges for bloodspot testosterone in term neonates at this age were < 0·4-2· 3 nmoljL in boys and < 0-4 nmoljL in girls. Figure 4 illustrates bloodspot testosterone concentrations in the preterm infants according to postnatal age. In general, the levels were higher than in term infants and boys' levels were distinct from girls'. The results in those infants tested serially are also shown in Fig. 4 . Testosterone levels were consistently low in three girls, whereas in the twelve boys there was a striking rise in testosterone levels with increasing postnatal age.
All four children with CAH were considered to be 'well controlled' at the time of the study, with testosterone levels below the detection limit at all sampling times and correspondingly low (and therefore adequately suppressed) 17-0HP concentrations apart from a small rise in the early morning (data not shown). Figure 5 illustrates the bloodspot testosterone and 17-0HP profiles from a girl before and during treatment for CAH. The baseline bloodspot testosterone concentration was> 40 nmol(L, well above the upper limit of the normal adult male plasma range (1G-30nmoljL). In response to replacement treatment with hydrocortisone and fludrocortisone, concentrations of both 17-0HP There are few data to compare regarding plasma testosterone concentration in term infants. Tapanainerrv' measured plasma testosterone in 44 term boys and 19 girls in cord blood and on days 1, 3 and 5, using 2 mL of blood per sample. Mean testosterone concentrations on day 5 were approximately 0·8 nmol/L and 0·13 nrnol/L in males and females respectively; no ranges were quoted. For the present study the bloodspots were those unused for routine newborn screening and were collected on days 6-9. The results are in general agreement with those of Tapanainen, allowing for the use of whole blood instead of plasma, and they also illustrate a similar sex difference.
Previous data from preterm infants are also sparse and mainly confined to cord blood samples.l-' In this study some girls show testosterone concentrations above the detection limit of the assay but levels are consistently lower than those in boys of similar postnatal age. The pattern of a significant rise in testosterone concentration at 4-8 weeks of age in term boys" is also seen in pre term boys tested serially, while results in girls remain consistently low. There are insufficient data to analyse differences associated with birth gestation but the bloodspot assay does allow such studies to be performed in a larger number of infants.
The use of bloodspot 17-0RP concentrations for the assessment of control in CAR is complicated by morning levels which are moderately raised when control, as assessed by 80 .j ... The bloodspot testosterone assay takes only slightly longer to complete than the conventional plasma assay and has equivalent sensitivity. The plasma reference range for prepubertal boys and girls is < O'5 nmol/L. Precision, although less satisfactory than for most non-extraction plasma steroid assays, is comparable to that reported for other assays utilizing elution and extraction procedures.I" and testosterone fell to normal levels within about 4 months. 
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growth rate, is adequate; II complete suppression of l7-0HP concentration throughout the day suggests overtreatment. It is difficult to define the upper limit for an 0800 h l7-0HP concentration that is still compatible with a reasonable replacement regimen, but a bloodspot 17-0HP concentration of up to 70-80 nrnol/L, equivalent to a serum l7-0HP concentration of less than 150nmolfL, has been proposed.S!' However, as illustrated by the present study, concomitant measurement of bloodspot testosterone concentrations offers an additional method to improve the assessment of the adequacy of control in CAH. Serum or bloodspot testosterone measurements are not suitable for monitoring CAH therapy in pubertal or post-pubertal boys, and in this situation serum or bloodspot androstenedione measurements have an advantage.
A bloodspot testosterone assay of sufficient precision and sensitivity has been established to complement bloodspot assays already available for several other steroid hormones.I!" As well as being useful to monitor treatment in conditions such as CAH, the small blood volumes required for this assay make the technique suitable for studying further the various factors associated with the unique postnatal changes in testosterone levels in preterm and term male infants.
